Skip to main
MAZE
MAZE logo

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc is strategically advancing its pipeline with two promising precision medicine programs, MZE829 and MZE782, targeting chronic kidney disease through its innovative Compass platform. Recent Phase 1 results for MZE782 demonstrated substantial pharmacodynamic activity, including a 42-fold increase in urinary phenylalanine without evidence of tubular injury, thus bolstering confidence in its therapeutic potential and safety profile. Furthermore, the compound's compelling efficacy data suggests that it may serve as a competitive hemodynamic modulator in the treatment landscape, particularly in chronic kidney disease, positioning the company for significant market share opportunities.

Bears say

Maze Therapeutics Inc's stock outlook is negatively impacted by multiple systemic safety liabilities that could constrain the effectiveness of its therapies, specifically those targeting chronic kidney disease. The company's two primary programs, MZE782 and MZE829, face significant risks including potential failures in clinical studies, challenges in securing regulatory approval in major markets, and difficulties in achieving projected peak commercial revenues due to market size and pricing issues. Collectively, these factors contribute to uncertainty in the company's ability to deliver on investor expectations and create a viable path to profitability.

MAZE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 6 analysts, MAZE has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.